Antonio G. M.
- Country
- Spain
- Department
- N/A
Research Overview
- A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705.
- A Global, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
- Long-term Safety and Efficacy Evaluation of Pabinafusp Alfa in Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
Data & Insights
Has run more than one trial at 49 of 132 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating complex hematological conditions, with particular focus on Acute Myeloid Leukemia (AML) and complications related to hematopoietic stem cell transplantation.
- Stem cell transplant therapies
- Post-transplant complications management
- Leukemia treatment innovations
Advanced therapeutic approaches in transplant-associated conditions including thrombotic microangiopathy.
Infectious Diseases
Expertise in managing severe fungal infections, particularly invasive pulmonary aspergillosis, with focus on treatment-resistant cases.
- Antifungal combination therapies
- Refractory infection management
- Pulmonary infection treatments
Specialized approaches in treating complex respiratory fungal infections using novel therapeutic combinations.
Therapeutic Innovation
Development and implementation of novel treatment approaches including targeted molecular therapies for hematologic malignancies.
- Gene-targeted treatments
- Maintenance therapy protocols
- Adjunctive treatment strategies
Focus on personalized treatment approaches for patients with specific genetic alterations in KMT2A/MLL, NPM1, and NUP98 genes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.